Study S000714

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06068946
Acronym: VENTURE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 176
Start: 2023-08-31
Primary completion: 2024-02-27
Lead sponsor: Viking Therapeutics, Inc.
Conditions: Weight Loss
Interventions: BIOLOGICAL:VK2735; BIOLOGICAL:Placebo
Results posted: FALSE

Registered primary outcomes

Percent (relative) change from baseline to Week 13 in body weight [13 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011224	Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Bays HE, Obesity (Silver Spring, Md.)	2026	Randomized trial	PMID 41508550 DOI	cites ClinicalTrials.gov:NCT06068946; registry reference DERIVED:41508550